Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
Clinical trial NCT04564313 · UNKNOWN
Trial details
- NCT number
- NCT04564313
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-21
- Primary completion
- 2022-09-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.